Ashish M. Kamat: What is the impact of sex on outcomes in NMIBC?
Ashish M. Kamat, President, IBCG, shared a post on X:
“What is the impact of sex on outcomes in NMIBC? Check out our latest study in European Urology Oncology led by Niyati Lobo.”
We combined two large datasets to examine the impact of sex in NMIBC: SEER-Medicare & UROMOL In the SEER-Medicare cohort, females had (compared to men):
-recurrence
-progression
-BC-specific mortality
However, analysis of the UROMOL cohort revealed no sex-specific differences in tumor biology across genomic, transcriptomic, and spatial proteomic domains.
Why does this matter?
Highlights limitations of SEER-Medicare – true incidence of recurrence/progression challenging to determine Integrating population-based data with molecular research is crucial to understanding of NMIBC
Beyond tumor biology, other influences onsex disparities in NMIBC include:
-Immune responses
-Sex hormones
-Bladder microbiome”
“Thank you to European Urology Oncology for publishing this collaborative effort between Cambridge University Hospitals NHS, MD Anderson Cancer Center, Aarhus Universitet, University of Texas Medical Branch.”
Authors: Niyati Lobo, Zhigang Duan, Akshay Sood, Hui Zhao, Sia V. Lindskrog, Lars Dyrskjot, Sharon H. Giordano, Stephen B. Williams, Kelly K. Bree and Ashish M. Kamat.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023